Download PDF
Thromb Haemost 1997; 77(06): 1096-1103
DOI: 10.1055/s-0038-1656119
Clinical Studies
Schattauer GmbH Stuttgart

Prospective Evaluation of the Prevalence of Haemostasis Abnormalities in Unexplained Primary Early Recurrent Miscarriages

The Nímes Obstetricians and Haematologists (NOHA) Study
Jean-Christophe Gris
1   The Consultations et Laboratoire d’Hématologie, CHU, Nimes
2   Laboratoire d’Hématologie, Faculté de Pharmacie, Montpellier
,
Sylvie Ripart-Neveu
3   Service de Gynécologie-Obstétrique, CHU NTmes
,
Claude Maugard
1   The Consultations et Laboratoire d’Hématologie, CHU, Nimes
,
Marie-Laure Tailland
3   Service de Gynécologie-Obstétrique, CHU NTmes
,
Sophie Brun
1   The Consultations et Laboratoire d’Hématologie, CHU, Nimes
,
Christophe Courtieu
3   Service de Gynécologie-Obstétrique, CHU NTmes
,
Christine Biron
4   Laboratoire d’Hématologie, CHU, Montpellier
,
Méderic Hoffet
3   Service de Gynécologie-Obstétrique, CHU NTmes
,
Bernard Hédon
5   Service de Gynécologie-Obstétrique, CHU, Montpellier, France
,
Pierre Marés
2   Laboratoire d’Hématologie, Faculté de Pharmacie, Montpellier
› Author Affiliations
Further Information

Publication History

Received 09 August 1996

Accepted after revision 06 March 1997

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The prevalence of haemostasis abnormalities was evaluated in 500 consecutive women with unexplained primary recurrent miscarriages. Two matched reference groups with no antecedent of miscarriage were studied: 100 healthy mothers and 50 childless women.

In the prospective part of the study, we found 9.4% of the patients (95% C.I.: 6.8-12%) with an isolated factor XII deficiency, 7.4% of the patients (5.0-9.8%) with primary antiphopholipid antibodies, 47% of the patients (42.6-51.4%) with an insufficient response to the venous occlusion test and an isolated hypofibri- nolysis was found in 42.6% (38.2-47%) of the patients (reference groups: respectively 0/150, 3/150, 2/150, 2/150, pclO’3). Willebrand disease, fibrinogen deficiency, antithrombin, protein C or protein S deficiencies were not more frequent in recurrent aborters than in members of the reference groups. In the retrospective part of the study, cases of plasma resistance to activated protein C were not abnormally frequent.

Patients had higher Willebrand factor antigen (vWF), tissue-type plasminogen activator antigen (t-PA), plasminogen activator inhibitor activity (PAI) and D-dimers (D-Di) than the reference women. Values of vWF, t-PA, PAI and D-Di were altogether correlated but were not related to C-reactive protein concentrations. Among patients, those with an antiphospholipid syndrome and those with an insufficient response to the venous occlusion test had higher vWF, t-PA, PAI and D-Di values than the patients with none of the haemostasis-related abnormalities.

Thus, factor XII deficiency and hypofibrinolysis (mainly high PAI) are the most frequent haemostasis-related abnormalities found in unexplained primary recurrent aborters. In patients with antiphospholipid antibodies or hypofibrinolysis, there is a non-inflammatory ongoing chronic elevation of markers of endothelial stimulation associated with coagulation activation. This should allow to define subgroups of patients for future therapeutic trials.

 

  • References

  • 1 Poland BJ, Miller JR, Jones DC, Trimble BK. Reproductive counselling in patients who have had a spontaneous abortion. Am J Obstet Gynecol 1977; 127: 685-691
    CrossrefPubMedGoogle Scholar
  • 2 Stray-Pederson B, Stray-Pederson S. Etiologic factors and subsequent reproductive performances in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol 1984; 148: 142-146
    PubMedGoogle Scholar
  • 3 Berry CW, Brambati B, Eskes TKAB, Exalto N, Fox H, Geraedts JPM, Gerhard I, Gonzales-Gomes F, Grudzinskas JG, Hustin J, Jouppila P, Lind-blom BKA, Mantoni M, Montenegro N, Nogales-Femandes F, O’Rahilly R, Pederson JF, Peters PWJ, Regan L, Rushton DI, van StraatenHWM, Tarlatzis BC, Wells M. The Euro-team early pregnancy (ETAP) protocol for recurrent miscarriage. Hum Reprod 1995; 10: 1516-1520
    CrossrefPubMedGoogle Scholar
  • 4 Haan L, Lundberg PA. Congenital hypofibrinogenemia and recurrent abortion. Br J Obstet Gynaecol 1978; 85: 790-793
    CrossrefPubMedGoogle Scholar
  • 5 Duckert F. The fibrin stabilizing factor, factor XIII. Blut 1973; 26: 177-179
    CrossrefPubMedGoogle Scholar
  • 6 Triplett DA, Exner EN. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol 1989; 21: 123-131
    CrossrefPubMedGoogle Scholar
  • 7 Schved JF, Gris JC, Neveu S, Dupaigne D, Mares P. Factor XII congenital deficiency and early spontaneous abortion. Fertil Steril 1989; 52: 335-336
    CrossrefPubMedGoogle Scholar
  • 8 Gris JC, Neveu S, Marés P, Biron C, Hedon B, Schved JF. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 1993; 122: 606-615
    PubMedGoogle Scholar
  • 9 Constant G, Gouault-Heilmann M, Martinolli JL. Heparin inactivation during blood storage. Its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamol – CTAD mixture. Thromb Res 1983; 31: 365-374
    CrossrefPubMedGoogle Scholar
  • 10 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung der Fibrinogene. ActaHematol (Basel) 1957; 17: 237-246
    PubMedGoogle Scholar
  • 11 Halbmayer WM, Haushofer A, Angerer V, Fischer M. The discrimination of factor XII deficiency and lupus anticoagulant. Thromb Haemost 1996; 75: 698-699
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Odegard OR, Lie M, Abildgaard U. Heparin cofactors activity measured by an amidolytic method. Thromb Res 1975; 06: 287-294
    CrossrefPubMedGoogle Scholar
  • 13 Martinolli JL, Stocker K. Fast functional protein C assay using protac, a novel protein C activator. Thromb Res 1986; 43: 253-254
    CrossrefPubMedGoogle Scholar
  • 14 Wolf M, Boyer-Neumann C, Martinolli JL. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 1989; 04: 1144-1145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Cejka J. Performance characteristics of a commercial kit for assay of factor VUI-related antigen. Clin Chem 1984; 30: 1512-1516
    PubMedGoogle Scholar
  • 16 Caen J, Larrieu MSamama. eds L’hémostase. Méthodes d’exploration et diagnostic pratique. Paris: Expansion Scientifique Fraçaise; 1975: 256
    Google Scholar
  • 17 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three monoclonal antibodies. Thromb Haemost 1985; 54: 684-687
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Eriksson E, Ranby M, Gysander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 91-101
    CrossrefPubMedGoogle Scholar
  • 19 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151
    CrossrefPubMedGoogle Scholar
  • 20 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874
    PubMedGoogle Scholar
  • 21 Schleider NA, Nachman RL, Jaffe EA, Coleman N. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
    PubMedGoogle Scholar
  • 22 Triplett DA, Brandt JT, Kaczar D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
    CrossrefPubMedGoogle Scholar
  • 23 Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989; 62: 892-896
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Rosove MH, Ismail M, Koziol BJ, Runge A, Kasper CK. Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 1986; 68: 472-478
    PubMedGoogle Scholar
  • 25 Reber G, Arvieux J, Comby E, Degenne D, de MoerlooseP, Sanmarco M, Potron G. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemost 1995; 73: 444-452
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Rosen S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-260
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Boneu B, Bes G, Pelze H, Sié P, Bocalon H. D-dimer, thrombin-antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991; 65: 28-32
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Braulke I, Pruggmayer M, Melloh P. Factor XII (Hageman) deficiency in women with habitual abortion: new subpopulation of recurrent aborters?. Fertil Steril 1993; 59: 098-101
    CrossrefPubMedGoogle Scholar
  • 29 Mannhalter C, Fisher M, Hopmeier P, Deutsch E. factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 01: 259-263
    PubMedGoogle Scholar
  • 30 Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995; 92: 850-854
    CrossrefPubMedGoogle Scholar
  • 31 Sanson BJ, Friederich PW, Simioni P, Zanardi S, Huisman MV, Girolami A, ten CateJW, Prins MH. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-388
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Preston FE, Rosendaal FR, Walker ID, Briët E, Bemtorp E, Conard J, Font-cuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der MeerFJM. Increased foetal loss in women with heritable thrombophilia. Lancet 1996; 348: 313-316
    CrossrefPubMedGoogle Scholar
  • 33 MacLean MA, Cumming GP, McCall F, Walker ID, Walker JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994; 101: 103-106
    CrossrefPubMedGoogle Scholar
  • 34 Goldberg SN, Conti-Kelly AM, Greco TP. A family study of anticardiolipin antibodies and associated clinical conditions. Am J Med 1995; 98: 473-479
    PubMedGoogle Scholar
  • 35 Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S. Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol 1991; 77: 854-858
    PubMedGoogle Scholar
  • 36 Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid- beta2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75-81
    CrossrefPubMedGoogle Scholar
  • 37 Aoki KA, Dubkiewicz AB, Matsuura E, Novotny M, Kaberlejn G, Gleicher N. Clinical significance of beta2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: correlation with conventional antiphospholipid antibody detection system. J Obstet Gynecol 1995; 172: 926-931
    CrossrefPubMedGoogle Scholar
  • 38 Shelton AJ, Harger JH, Dorman JS, Kuller LH, LaPorte RE, Gill III TJ. Association between familial autoimmune diseases and recurrent spontaneous abortions. Am J Reprod Immunol 1994; 32: 82-87
    CrossrefPubMedGoogle Scholar
  • 39 Gris JC, Schved JF, Neveu S, Aguilar-Martinez P, Dupaigne D, Mares P. Impaired fibrinolytic capacity and early recurrent abortion of unknown etiology. Br Med J 1990; 300: 1500
    CrossrefPubMedGoogle Scholar
  • 40 Patrassi GM, Sartori MT, Ruffatti A, Viero M, Di LenardoL, Cazzanello D, Ghirardello A, Boeri G, Saggiorato G, Girolami A. Fibrinolytic pattern in recurrent spontaneous abortions: no relationship between hypofibrinolysis and anti-phospholipid antibodies. Am J Hematol 1994; 47: 266-272
    CrossrefPubMedGoogle Scholar
  • 41 Petaja J, Rasi V, Vahtera E, Myllyla G. Familial clustering of defective release of t-PA. Br J Haematol 1991; 79: 291-295
    CrossrefPubMedGoogle Scholar
  • 42 Jorgensen M, Bonnevie-Nielsen V. Increased concentrations of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175-180
    CrossrefPubMedGoogle Scholar
  • 43 Juhan-Vague I, Vague P, Alessi MC. Relationship between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab 1987; 13: 331-336
    PubMedGoogle Scholar
  • 44 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients – Relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Juhan-Vague I, Aillaud MF, De CockF. The fast-acting inhibitor of tissue- type plasminogen activator is an acute phase reactant protein. In: Davidson JF, Donati MB, Coccheri S. eds Progress in fibrinolysis (vol VII) Edinburgh: Churchill Livingstone; 1985: 146-149
    Google Scholar
  • 46 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de LooJCW. for the E.C.A.T Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641
    CrossrefPubMedGoogle Scholar
  • 47 Winkelstein Jr W, Stenchever MA, Lilienfeld AM. Occurrence of pregnancy, abortion and artificial menopause among women with coronary heart disease. J Chron Dis 1958; 07: 273-286
    CrossrefPubMedGoogle Scholar
  • 48 Rushton DI. Placental pathology in spontaneous miscarriage. In: Early pregnancy loss. Beard RW, Sharp F. (eds) London: Springer; 1988. pp 149-156
    CrossrefGoogle Scholar
  • 49 Archipoff G, Beretz A, Freyssinet JM, Klein-Soyer C, Brisson C, Cazanave JP. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumor necrosis factor, thrombin or phorbol ester. Biochem J 1991; 273: 679-684
    CrossrefPubMedGoogle Scholar
  • 50 Mallmann P, Werner A, Krebs D. Serum levels of interleukin-2 and tumor necrosis factor alpha in women with recurrent abortion. Lancet 1994; 163: 1367
    PubMedGoogle Scholar
  • 51 Ferari DA, Gilles PA, Klein NW, Nadler D, Weeks BS, Lammi-Keefe CJ. Rat embryo development on human sera is related to numbers of preyious spontaneous abortions and nutritional factors. Am J Obstet Gynecol 1994; 170: 228-236
    CrossrefPubMedGoogle Scholar